Regulators said the deal would give Amgen unfair leverage to block competition for Horizon medications.
The U.S. is attempting to block a proposed $26 billion acquisition of Horizon Therapeutics by biotech drug developer Amgen on antitrust grounds.
The Federal Trade Commission said Tuesday that the deal, announced in December, would give Amgen unfair leverage to block competition for Horizon medications. The FTC said the deal would entrench Horizon’s monopoly position on treatments for thyroid eye disease and chronic refractory gout.The Thousand Oaks company said in December that the acquisition would allow it to expand into rare disease treatments.
Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease. The FTC said Tuesday that the deal would allow Amgen to use rebates on its existing drugs to pressure bill payers like pharmacy benefit managers into favoring Tepezz and Krystexxa, a treatment for chronic refractory gout.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Horizon shares sink on report that FTC will sue to block takeover by AmgenShares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen...
Consulte Mais informação »
FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - sourceThe U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC , a person familiar with the matter told Reuters.
Consulte Mais informação »
Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen dealThe deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Consulte Mais informação »
FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission is preparing to block Amgen’s $28 billion deal to buy Horizon Therapeutics
Consulte Mais informação »
FTC sues to block Amgen acquisition of Horizon TherapeuticsThe deal was a bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Consulte Mais informação »
FTC sues to block $27.8 billion acquisition of Horizon Therapeutics, which has U.S. headquarters in DeerfieldThe suit marks the first time the FTC has tried to stop a pharmaceutical merger in years
Consulte Mais informação »